Search

Displaying results 2761 - 2770 of 9670 in total
  1. Drug

    Calusterone

    go.drugbank.com/drugs/DB01564
    ExperimentalIllicit

    A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.

    Synonyms: 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one
  2. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    The use of Peginterferon alfa-2a has largely declined since newer interferon-free antiviral therapies have been developed. … Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C.

  3. Drug

    Fennel

    go.drugbank.com/drugs/DB15615
    Approved

    Mixtures: Digestion-Bloating-Gas
  4. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. … In the body, both dehydroascorbic acid and ascorbic acid have similar biological activity as antivirals but dehydroascorbic acid also has neuroprotective effects.

  5. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285]. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.

  6. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    [A216148, A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing … tumour cells in the CAR T cell preparation.

    Categories: Receptors, Antigen, T-Cell, CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
  7. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … Therefore, significant research has been put into developing genetically targeted treatments.

  8. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas. … It is a synthetic aromatic retinoid.

  9. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin … [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650]

  10. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

    Products: Bretylate Inj 50mg/ml, Bretylium Tosylate Inj 50mg/ml